Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-02 15:44:32 - browse：2196

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Amylyx ALS drug fails large clinical trial

explore

WSS

Startling documents reveal new facets of Sacklers' opioid empire

What it’s like to watch children die of measles

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

The drug industry has found itself all alone in Washington

Insmed lung disease drug hits target in key Phase 3 trial

focus

Wikipedia

focus

Novavax promises a turnaround & Lilly roils the obesity market

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Trump demands the U.S. pay no more for drugs than other countries … again

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

How one medical school became remarkably diverse

Average age of first period drops to 11.9 years, study shows

As demand for Covid shots wanes, Moderna seeks its next success

CDC marks new Covid

Psychedelics group wrestles with new pharma identity

Amylyx ALS drug failure raises questions and concerns

focus

Amylyx ALS drug failure raises questions and concerns

Health insurers say they are turning to AI to cut costs, improve care

Precocious puberty in girls comes with mental health risks

Heat waves linked to early deliveries, preterm births in new study

With psoriasis trial ahead, Alumis raises $259 million

Latest bird flu infection made farmworker sicker than earlier cases

Wikipedia

hotspot

explore

leisure time